Biomarkers 2019 | London | UK | Allied Conferences | Meetings

Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academies Conferences

Theme

Biomarkers: Heralding a Better Future

- Biomarkers 2019

Welcome Message

Biomarkers 2019 organizing committee with great honour extending you a warm invitation to attend the International Conference on Biomarkers which is slated to held in March 11-12, 2019 in London, UK.

International Conference on Biomarkers 2019 is a designed cluster conference with theme “Biomarkers: Heralding a Better Future” contemplating to ground scientific personnel from the area of Biological sciences into genomics & proteomics, analytical & biophysical technologies and computational & statistical analysis. Our conference will extend the holistic scientific approach to validate the existing and development of novel biomarkers as to better understanding of diseases and diagnosis.

The Conference will offer a wide platform to share vital and recent innovations in the arena of Biomarkers, Cancer Biomarkers, Immunology, Biotechnology, Neurology, Pharmacology, Personalized medicine, Molecular Biology, Genetic and Protein engineering. It also has a wonderful space for both scientific presentations like oral, poster and commercial exhibition.

Biomarkers 2019 have an exciting program that will allow the participants to reflect upon and celebrate the past accomplishments, renew friendships, extended networking opportunities, foster communication between speakers and delegates and jointly unveil current and future research directions.

It is an exciting for Biomarkers researchers and we hope that you will have a useful and fun filled time in London at this special Conference Biomarkers 2019.

We look forward to welcoming you all for what promises to be an outstanding event

Past Conference Report

to express a great appreciation to all the plenary speakers and participants joined this international network and visited London, to make their deposit by their high quality presentations, exciting and interesting discussions at the unique atmosphere of this fruitful scientific gathering.

AAC hosted International Conference on Biomarkers during March 11-12, 2019 at London, UK based on the theme “Biomarkers: Heralding a Better Future”.

Biomarkers 2019 was marked with multiple sessions, keynote presentations and panel discussions. We received copious involvement and response from young and brilliant researchers, business delegates and talented communities who made this Conference as one of the most successful and productive events in 2019 from AAC.

Biomarkers 2019 started with the welcome and opening remarks of the conference host and the proceedings also went through interactive sessions and panel discussions.

The meeting was carried out through different sessions, in which the discussions were held on the following major scientific topics:

Biomarkers
Biomarkers research in Immuno-Oncology
Molecular & Genetic Biomarkers
Biomarkers in Oncology

Conference carried out by various scientific-sessions and plenary lectures in which the following Speakers were highlighted as Keynote speakers:

Radhashree Maitra, Yeshiva University, USA
Shaoguang Li, University of Massachussets Medical School, USA

AAC has taken the privilege of felicitating the Organizing Committee, Keynote Speakers and all the speakers who supported for the grand success of this event. We would like to congratulate the awardees for their outstanding performance in the field of Biomarkers and express our gratitude to all the attendees who put their efforts in presentations and sincerely wishes them success in future endeavours.

With the unique feedback from the Conference, AAC would like to announce the commencement of the International Conference on Biomarkers and Applied Clinical Research Technology.

Bookmark your dates: We hope to see you at Clinical Research 2019 at Frankfurt, Germany during October 10-11, 2019.

Meet again @ Clinical Research 2019

Scientific Sessions/Tracks

Session On: Biomarkers

Biological markers are measurable indicators that can be used

to predict the risk of disease, to enable the diagnosis of disease, effects of treatment and to modify pathological processes and improving treatment selection and to monitor the results of therapeutic interventions. Biomarkers can be a gene, gene product, protein encoded by gene, hormone or an enzyme.

Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK

Session On: Biomarkers in Oncology

Biomarkers plays a major role in Oncology that are used in clinical research for risk assessment, differential diagnosis, determining nature of tumors, for screening purpose, to determine prognosis and drug dose-response to treatment. Biomarkers can predict behavior of tumor (benign/malignant), drug resistance. Biomarkers can establish the accuracy of diagnosis, can be associated to other investigations to suspect the type of Cancer.

Related Conferences: International Conference on Molecular Biology and Stem Cells, November 19-20, 2018 at Paris, France; 12th International Conference on Cancer Stem Cells and Oncology Research, March 15-17, 2019 at Rome, Italy; 9th European Congress on Breast Cancer, Women’s health and Therapeutics, February 25-27, 2019; 2nd World Congress on Stem Cells and Regenerative Medicine, March 14-15, 2019, London, UK

Session On: Biomarker research in Neuro-oncology

Neurology deals with diagnosis and treatment of disease conditions of central and peripheral nervous system and is one of the typical disciplines where personalized medicine has becoming an important part of clinical trials. Different issues in neurology are to be discussed in relation to personalized medicine and diagnostic, prognostic and predictive blood biomarkers.

The role of biomarkers & personalized medicine in neuro-oncology is becoming extensively important. The actual state of knowledge in several domains of neurology (neuro-oncology, cerebrovascular, neurodegenerative, and demyelinating diseases) are to be discussed.

Session On: Biomarker research in Immuno-oncology

Cancer therapy is continues to evolve, with immune-oncology offering a new approach to treatment that holds significant promise. If cancer is detected, patients undergo a variety of tests of diagnosis, prognosis, and treatment decision-making. The need for multiple, diverse diagnostic approaches to guide treatment decision-making in oncology is not likely to change, and the emergence of groundbreaking immunotherapeutic drugs that work by stimulating the immune system to attack a tumour is only adding to the diagnostic complexity. Biomarker-based CDx are essential to guide treatment decisions and are a valuable tool to aid in patient selection for clinical testing of new I/O drugs.

Tissue-based biomarkers are proving to be invaluable for helping to stratify patients based on the immune context of a tumour and the patient-specific characteristics of the tumour microenvironment as well as interactions between tumour and immune cells and between a tumour and surrounding tissues. Tissue context biomarkers can capture this diversity and complexity, and biomarker-based CDx can drive individualized treatment decisions.

Session On: Cardiovascular Biomarkers

There are number of cardiovascular disease biomarkers that are available used for clinical research as diagnostic, prognostic or predictive types. Many of these biomarkers have been vigorously tested to assess their clinical utility across different patients with atherosclerotic CVD. The desirable characteristics of any cardiovascular biomarker includes measurement should be easy, preferably at point-of-care over a short period of time with adequate precision and accuracy. These biomarkers can reflect pathophysiologic process of cardiovascular diseases, and also may be able to give information about prognosis and assist guide clinical decision making without duplicating any information that is already available clinically.

Biomarkers evaluating prognostic outcomes should report discrimination, calibration and reclassification in patients by evaluating statistical models with and without the biomarker in order to demonstrate their added value over traditional and other commonly used biomarkers. Genetic biomarkers are at the forefront of being evaluated for added utility and they too need rigorous assessments to evaluate their relations with the CVD and for their added advantage over traditional risk factors. Utilizing biomarkers as surrogate end points for predictive and prognostic values in clinical trials will likely dictate our future of CVD treatment, and will also open up avenues to evaluate biomarkers as possible targets for drug delivery and development.

Session On: Genomics

Recent research of Biotechnology and Genomics signifies the advancement of biomarkers to detect individual disease risk and enhance diagnostic classification to better inform personalized treatment. The identification and development of biomarkers for personalized, preventive and predictive medicine was a major impulse of Human Genome Project.

Biomarkers related to Genomics measure changes in the quantity or nature of nucleic acids . DNA-based biomarkers include copy number variation, mutations(including polymorphisms, somatic mutations, and other genetic variants), and epigenetic modifications. RNA expression-based biomarkers include quantification of mRNA, microRNA and long noncoding RNA expression.

Session On: Proteomics

Serum consists of number of small sized peptides, as a result of various cellular activities, called as the serum proteome. Proteomics has been widely used to study wide range of medical field includes drug development and Biomarker discovery. By correlating with other advanced techniques in genomics and bioinformatics, proteomics has the extensive contribution to biomarker identification and to revolutionize drug development process.

Session On: Molecular & Genetic Biomarkers

Molecular Biomarkers are alteration expressions of structures of nucleic acids, proteins and proteoglycans Cancer diagnosis is currently undergoing a standard shift with the incorporation of molecular biomarkers as part of routine diagnostic panel. Molecular alteration ranges from the DNA, RNA, microRNAs (miRNAs) and proteins. The miRNAs are recently discovered small non-coding endogenous single-stranded RNAs that critically regulates the development, invasion and metastasis of cancer. They are altered in cancers and have the potential to serve as diagnostic markers for cancer.

Session On: Biomarkers and Transcriptomics

Transcriptomics referred to as gene expression profiling is the quantitative study of genes expressed in a biological state. Advanced technologies enables quantitative assessment of all expressed genes (transcriptome) in a given tissue. These advancements provide a powerful tool for understanding biological systems and for developing novel biomarkers. Transcriptomics has powerful impact on the field of cardiovascular biomarkers and several transcriptome biomarkers are accessible for clinical research. Transcriptomics have shown that aggregate measures comprised of multiple genes are also informative as biomarkers of complex disease.

Session On: Biomarkers in Pharmacology

Biomarkers are major tools in drug development and pharmaceutical research. Biomarkers have been recognized in making the drug development process to be more efficient and have become an essential part of Pharmacology and pharmaceutical research. Number of biomarkers are expected that will ultimately transition into the clinical laboratory.

Biomarkers demonstrate drug dose–response relationships between biomarker changes, onset of injury, and severity of injury that correspond to progression of the injury.

Session On: Biomarkers in Drug discovery and Drug Development

The Biomarkers have incredible potential to affect rate of success of clinical trials and identify new drug targets and advance diagnostic assays for early detection of disease. Biomarker development originates in the drug discovery phase and leads to clinical validation stage. In the target, discovery and validation stage biomarkers are used to identify and justify targets for therapy.

Biomarkers should have consistent characteristics with an acceptable sensitivity and specificity representing a specific toxicity or therapeutic effect of the drug, a specific physiological response to a treatment, a pathological progression, or a physiological factor.

Session On: Diagnostic and Therapeutic biomarkers

Biomarkers used to detect the presence of a disease or condition and to identify individuals with subtype of disease. Diagnostic Biomarkers allows the development of screening programs of certain cancers (cellular and molecular pathology). Therapeutic biomarkers has involved in huge therapeutic range in treating cardiovascular, rare diseases, infectious diseases, inherited diseases.

Session On: Biomarkers in Personalized medicine

Pharmacogenomics and Personalized medicine is an advanced practice of medicine that implies on individual’s genetic profile to guide decisions made to the diagnosis, prevention and treatment of particular diseases to the right patient at the right time giving right therapy. There are number of personalized medicines than before in clinical pipeline across many diseases. Pharmacogenomics & Personalized medicine is advanced through data from the Human Genome Project. Biomarkers plays an important role in making use of pharmacogenomics, pharmaco proteomics for development of personalized medicine.

Session On: Biomarkers in Clinical research

Clinical research describes many different elements of scientific investigation. Simply put, it involves human participants and helps translate basic research (done in labs) into new treatments and information to benefit patients.

Session On: Biomarkers for Disorders

“Candidate biomarker” is term applied to any biological feature related with a disorder. Psychiatric disorders has a long history in search of biomarkers, with recent studies consider molecular markers, like platelet imipramine binding or behavioral markers, such as smooth pursuit eye movements in schizophrenia condition and fear extinction in people with anxiety. Recent searches looking forward to investigate on blood biomarkers such as brain-derived neurotrophic factor and cytokines in people with schizophrenia or depression and More high-tech searches such as the use of proteomics to define signatures of proteins that are altered in blood.

More research is going on to investigate socio-environmental, molecular, neuroimaging findings related with Psychiatric disorders such as Alzheimer disease, schizophrenia to detect particular signs of the disorder. Most advanced project in this aspect is the Alzheimer’s Disease Neuroimaging Initiative which was funded jointly by the U.S. National Institutes of Health, the pharmaceutical industry and other organizations.

Session On: Digital Biomarkers

Biomarkers are consumer generated physiological and behavioural measurables by means of digital tools such as portables, wearables, implantables with high efficiency. Data collected from these biomarkers is used in helping to reshape the understanding of health and disease that will have impact on individual’s relationship to environment is assessed and how treatment effectiveness is determined. Digital biomarkers also represent an opportunity to capture clinically meaningful, objective data. These biomarkers are rapidly changing the way we conduct research, understand disease progression, and consumers in care.

Session On: Imaging Biomarkers

Imaging biomarkers have a crucial role is new drug development. Drug development has been changed in last two decades because massive progresses in molecular biology have been made that is leading to detailed understanding of the genetic abnormalities in different diseases. The advancements in medical imaging offer the opportunity of using imaging biomarkers to fasten the drug development process.

Imaging Biomarkers can be Anatomical, functional and molecular characterized and these anatomical biomarkers could be the only imaging surrogate endpoints that can be accepted in cancer treatment. Molecular imaging biomarkers target-specific. Functional imaging biomarkers have the advantage of being downstream markers that probe general capabilities of disease, including cell death, proliferation, glycolysis, tumor invasiveness, angiogenesis, inflammation, fibrosis and they are used as pharmacodynamic biomarkers.

Session On: Biomarkers and Next Generation Sequencing

Next Generation sequencing is sequencing technology to provide powerful insights into genetic mutations, DNA sequencing, molecular networks underlying disease for a broad set of genes. NGS technique promise to remodel huge areas in clinical research, validation and analysis of sequencing-based biomarkers. NGS provide positional sequencing enabling access to better and more accurate sequence information.

Session On: Advancements in Biomarkers

Use of biomarkers and diagnostic assessments continue to evolve with more uses and introduction of higher efficient sensitivity assays. These tests are powerful tools in clinical care approaching various different therapeutic areas such as Oncology, Immunology, Cardiology, and Endocrinology. Recent advancements of Biosensors to detect biomarkers in cancer treatment.

Session On: Applications of Biomarkers

Biomarkers are used as diagnostic tools for disease conditions accurately, to identify high risk individuals and to effectively prognosticate, treat patients with disease, targeting also specific biological sites. Advances in genomics, proteomics, metabolomics and bioinformatics have allowed discovering several biomarkers.

Market Analysis

Global market analysis:

The market of biomarker technologies is relied upon to achieve USD 74.51 Billion by 2022 from USD 46.97 Billion in 2017, at a CAGR of 9.7% during the time frame of forecast.

While critical advances have been made in the zone of biomarkers, making an interpretation of them into valuable clinical assays is dreary and a prime obstacle to the clinical utilization of these Biomarkers. The development of this market is driven by factors like expansion of healthcare expenditure, increasing the funding of R&D, increasing the utility of biomarkers for the purpose of diagnostics and rising the research of Biomarkers.

Depending on the product type, the market of Biomarker technologies is divided into instruments, services and programming/informatics. In 2017, the consumables portion was relied upon to represent the biggest share of the market because of their bigger sales volume when compared with instruments. The market of consumables is further fragmented into kits, reagents and columns of chromatography. In 2017, the segments of kits and reagents represented the biggest in the market of consumables.

By profiling innovation, the Biomarkers advancements market is characterized into immunoassay, PCR, mass spectrometry, NGS, chromatography, cytogenetics, and other different advances. The immunoassay portion represented the biggest share in 2017. This section is further classified into ELISA, western blot, and protein microarray. In 2017, the ELISA segment represented the biggest share in the market of immunoassay .

In 2017, North America represented the biggest share in the biomarkers market. Asia Pacific registered the most elevated development from 2017 to 2022 for the Biomarkers advances market. Factors like the rising rate of malignancy, developing geriatric population, and support from private and public associations for biomarker research are driving the development of this regional section.

Statistical analysis of members associated with Biomarkers

Market Analysis of Biomarkers by Region

Biomarkers Technologies Market, By Research Area:

Genomics
Proteomics
Metabolomics
Lipidomics
Other research types

Target audience

Hospitals and clinics
Research institutes and clinical research organizations
Market research and consulting firms
Authorities framing reimbursement policies for the use of cancer diagnostics
Companies offering kits/assays/platforms/technologies for biomarker testing
Pharmaceutical Companies

Major associations around the world

The Biomarker consortium
International society for oncology and Biomarkers
Biomarkers profile corporation
World molecular imaging society
European society of molecular imaging
Biomarkers society
Society of nuclear medicine and molecular imaging

Universities associated with Biomarkers

Top Universities in UK

University of Cambridge
University of Oxford
University College London
Imperial College London
University of London
Brunel University London
King's College London
Kingston University London
Birkbeck, University of London
Queen Mary University of London

Why to attend

With individuals from around the globe concentrated on finding out about Biomarkers and Clinical Research, this is your best chance to achieve the biggest collection of members from different famous speakers. Lead exhibitions, circulate data, meet with potential speakers/Delegates all around the globe which are chipping away at the exceptionally rising field of Biomarkers, and get name acknowledgment at this occasion. Incredibly famous speakers, the latest procedures, strategies, and the freshest updates in Biomarkers and Clinical Research fields are signs of this meeting.